EUVIMEDObjevte EUVIMED
Crossref

Outcomes based on induction regimens in pediatric kidney transplantation: a NAPRTCS and PHIS collaborative study

Daniella Levy Erez, Helen Pizzo, Nancy Rodig, Troy Richardson, Michael Somers, NAPRTCS investigators

Pediatric Nephrology · 2023

DOI: 10.1007/s00467-023-05955-5 ↗

At a glance

Journal article in Pediatric Nephrology, 2023. Written by Daniella Levy Erez and 5 co-authors. Institution: Children's Hospital of Philadelphia, Philadelphia, PA, USA. levy.erez.daniella@gmail.com. Major MEDLINE topics: Kidney Transplantation, Health Information Systems. Cited 3 times so far (Crossref); 25 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

BACKGROUND: Induction agent used at the time of kidney transplant is often based upon center practice and recipient characteristics. We evaluated outcomes across induction therapies among children enrolled in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) transplant registry with data in the Pediatric Health Information System (PHIS). METHODS: This is a retrospective study of merged data from NAPRTCS and PHIS. Participants were grouped by induction agent: interleukin-2 receptor blocker (IL-2 RB), anti-thymocyte/anti-lymphocyte globulin (ATG/ALG), and alemtuzumab. Outcomes assessed included 1-, 3-, and 5-year allograft function and survival, rejection, viral infections, malignancy, and death. RESULTS: A total of 830 children transplanted between 2010 and 2019. At 1 year post-transplant, the alemtuzumab group had higher median eGFR (86 ml/min/1.73 m2) compared to IL-2 RB and ATG/ALG (79 and 75 ml/min/1.73 m2, respectively; P < 0.001); at 3 and 5 years, there was no difference. Adjusted eGFR over time was similar across all induction agents. Rejection rates were lower among the alemtuzumab group vs. IL-2RB and ATG (13.9% vs. 27.3% and 24.6%, respectively; P = 0.006). Adjusted ATG/ALG and alemtuzumab had higher hazard ratio for time to graft failure compared to IL-2 RB (HR 2.48 and HR 2.11, respectively; P < 0.05). Incidence of malignancy, mortality, and time to first viral infection was similar. CONCLUSION: Although rejection and allograft loss rates were distinct, the incidences of viral infection and malignancy were comparable across induction agents. By 3 years post-transplant, there was no difference in eGFR. A higher resolution version of the Graphical abstract is available as Supplementary information.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationHealth Information SystemsHumansChildAlemtuzumabAntibodies, Monoclonal, HumanizedRetrospective StudiesInterleukin-2Antilymphocyte SerumGraft RejectionImmunosuppressive AgentsGraft Survival

Author keywords

Induction agentsKidney transplantOutcomesPediatricsViral infections

Substances

AlemtuzumabAntibodies, Monoclonal, HumanizedInterleukin-2Antilymphocyte SerumImmunosuppressive Agents

Authors and institutions

  • Children's Hospital of Philadelphia, Philadelphia, PA, USA. levy.erez.daniella@gmail.com.
  • Schneider Children's Medical Center, Petach Tiqva, Israel. levy.erez.daniella@gmail.com.
  • Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Boston Children's Hospital, Boston, MA, USA.
  • Children's Hospital Association, Lenexa, KS, USA.

Cite

APA

Erez, D. L., Pizzo, H., Rodig, N., Richardson, T., Somers, M., & NAPRTCS investigators (2023). Outcomes based on induction regimens in pediatric kidney transplantation: a NAPRTCS and PHIS collaborative study. Pediatric Nephrology. https://doi.org/10.1007/s00467-023-05955-5

Vancouver

Erez DL, Pizzo H, Rodig N, Richardson T, Somers M, NAPRTCS investigators. Outcomes based on induction regimens in pediatric kidney transplantation: a NAPRTCS and PHIS collaborative study. Pediatric Nephrology. 2023. doi:10.1007/s00467-023-05955-5

BibTeX
@article{Erez2023,
  author = {Erez, Daniella Levy and Pizzo, Helen and Rodig, Nancy and Richardson, Troy and Somers, Michael and NAPRTCS investigators, NAPRTCS investigators},
  title = {Outcomes based on induction regimens in pediatric kidney transplantation: a NAPRTCS and PHIS collaborative study},
  journal = {Pediatric Nephrology},
  year = {2023},
  doi = {10.1007/s00467-023-05955-5}
}
Start for free →